Panelists review available treatment options for recurrent endometrial cancer, discussing their typical treatment approaches and the factors influencing treatment selection. Panelists also address insights from the RUBY trial, its updates, and the expanded FDA indication for dostarlimab, including the implications of these developments on treatment strategies and the potential benefits and challenges of broader use in patients.
Briefly comment on recent data updates presented for the RUBY trial and offer insights into the expanded FDA indication for dostarlimab in endometrial cancer.
Briefly comment on key takeaways from extended efficacy and safety data leading to the expanded approval.
How does the expanded indication approved for dostarlimab impact your treatment approach for advanced or recurrent endometrial cancer?
What are the potential benefits and challenges of using dostarlimab in a broader patient population?